Biogen concedes one board seat to Icahn (Dealscape

Carl Icahn will have at least one ally on the Biogen Idec Inc. board of directors. But will he get two? One day after a contentious shareholder meeting, the Cambridge, Mass. biotech firm announced Thursday that its own proxy solicitor has tallied "yes" votes for two of its own candidates and one of Icahn's candidates. The fourth board seat, which Icahn is also contesting, is "too close to call," Biogen said in a statement.

At Wednesday's meeting, which Biogen officials unexpectedly shut down for last-minute shareholder lobbying, Icahn and his deputies asserted they won two board seats, according to their own proxy vote. Icahn owns 5.6% of the company.

This is a free preview of the content available in The Deal Pipeline. Subscribers enjoy access to the full story, as well as second-to-none research tools.

To request a demo, or, if you are an existing user to The Deal Pipeline, log in to your account, please scroll down and click the button.

Dig deeper, with Pipeline.

96 company pages related to Biotech
53 in-depth reports of Reorganization plans in the Healthcare sector
28 in-depth transaction records for Carl Icahn
13 in-depth transaction records for Biogen Idec
10 years of news and analysis archives from the voice of The Deal Economy

Most searched keywords

Deutsche Bank
Birds Eye
Cadbury AG
Agrium Inc.
Skadden Arps
Revolution Money
Tandberg ASA
Aisling Capital
Ken Lewis
Natco

Forward-looking intelligence allows you time to act. View this video on our restructuring content to see how you can benefit from our expertise.
NOT A SUBSCRIBER? Biogen concedes one board seat to Icahn Posted on June 5, 2009 8:59 AM Carl Icahn will have at least one ally on the Biogen Idec Inc. board of directors. But will he get two? One day after a contentious shareholder meeting, the Cambridge, Mass. biotech firm announced Thursday that its own proxy solicitor has tallied "yes" votes for two of its own candidates and one of Icahn's candidates. The fourth board seat, which Icahn is also contesting, is "too close to call," Biogen said in a statement. At Wednesday's meeting, which Biogen officials unexpectedly shut down for last-minute shareholder lobbying, Icahn and his deputies asserted they won two board seats, according to their own proxy vote. Icahn owns 5.6% of the company. This is a free preview of the content available in The Deal Pipeline. Subscribers enjoy access to the full story, as well as second-to-none research tools. To request a demo, or, if you are an existing user to The Deal Pipeline, log in to your account, please scroll down and click the button. Dig deeper, with Pipeline. 96 company pages related to Biotech 53 in-depth reports of Reorganization plans in the Healthcare sector 28 in-depth transaction records for Carl Icahn 13 in-depth transaction records for Biogen Idec 10 years of news and analysis archives from the voice of The Deal Economy Most searched keywords Deutsche Bank Birds Eye Cadbury AG Agrium Inc. Skadden Arps Revolution Money Tandberg ASA Aisling Capital Ken Lewis Natco		EXISTING USERS Username Password Forget your password? Missing a product?

Sales Contact Michael Crosby mcrosby@thedeal.com 212.313.9325	Media Contact Martha Brown mbrown@thedeal.com 212.313.9218
Signing in signifies that you agree to our terms and conditions. View our privacy policy.